Neurogene Grants Inducement Stock Options for 96,450 Shares to New Employees

Neurogene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Neurogene President, CFO Christine Mikail Cvijic Sells 4,800 Common Shares for $166,407.28

Neurogene Says Cash Runway Extends into Q1 2029 After USD 134.8 Million Stock Offering

U.S. Stocks on the Move-general Mills, Meta, Lockheed Martin

Neurogene Prices USD 125 Million Follow-on Stock Offering at USD 30 Per Share

Neurogene - Prices Public Offering of 3.5 Mln Shares at $30 Per Share

Neurogene to Sell Shares in Secondary Offering

Neurogene Inc: Files for Offering of Common Stock, Pre-funded Warrants to Buy Common Stock; Size not Disclosed - SEC Filing

Neurogene Drops After Starting Equity Offering

Neurogene announces common stock offering, no amount given

Neurogene Commences Public Offering of Common Stock, Pre-funded Warrants

Neurogene Inc. Announces Proposed Public Offering

Neurogene - Proceeds to Fund Ngn-401 Development, Pre-commercial Activities, and General Corporate Purposes

Guggenheim Reaffirms Their Buy Rating on Neurogene (NGNE)

Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

Neurogene Says Ngn-401 Gene Therapy Shows Sustained Rett Syndrome Milestone Gains in Phase 1/2 Trial Through 30 Months

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome

Neurogene - Ngn-401 Generally Well-tolerated at 1E15 Vg Dose as of June 16, 2026

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)